Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome by Hua Bai, Dongming Zhou, Jinwen Liu, Jie He, Zhou Min, Wenyong Fan, Bing Chen, Yong Xu

“…This case suggests that bortezomib may be considered as a potential treatment option for SchS, in addition to anti-IL-1 therapies and bruton tyrosine kinase (BTK) inhibitors.…”
Get full text

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin by Ping Gu, Jennifer Wu, Elliot Newman, Franco Muggia

“…In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. …”
Get full text

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy by Ensi Voshtina, Huiya Huang, Renju Raj, Ehab Atallah

“…A common first-line therapy offered to qualifying patients includes ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase. Treatment of CLL with ibrutinib therapy is generally well tolerated; however, serious opportunistic infections are being reported in patients treated with ibrutinib. …”
Get full text

Severe Erosive Pill Esophagitis Induced by Crizotinib Therapy: A Case Report and Literature Review by Patrick Jung, Kyle J. Fortinsky, Zane R. Gallinger, Piero Tartaro

“…Previous case reports have described esophagitis thought to be secondary to crizotinib, an oral tyrosine-kinase inhibitor used in the treatment of anaplastic lymphoma kinase- (ALK-) positive non-small cell lung cancer (NSCLC). …”
Get full text

Relapsing Campylobacter jejuni Systemic Infections in a Child with X-Linked Agammaglobulinemia by Paola Ariganello, Giulia Angelino, Alessia Scarselli, Irene Salfa, Martina Della Corte, Arianna De Matteis, Patrizia D'Argenio, Susanna Livadiotti, Emma C. Manno, Cristina Russo, Andrea Finocchi, Caterina Cancrini

“…X-linked agammaglobulinemia (XLA) is a primary immunodeficiency of the humoral compartment, due to a mutation in the Bruton tyrosine kinase (BTK) gene, characterized by a severe defect of circulating B cells and serum immunoglobulins. …”
Get full text

Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases? by Stefania Gonfloni, Emiliano Maiani, Claudia Di Bartolomeo, Marc Diederich, Gianni Cesareni

“…The c-Abl tyrosine kinase is implicated in diverse cellular activities including growth factor signaling, cell adhesion, oxidative stress, and DNA damage response. …”
Get full text

A novel treatment strategy with hyperbaric oxygen of chronic osteomyelitis and pseudoarthrosis in a child with congenital hereditary sensory and autonomic neuropathy type 4 congeni... by Anders Kjellberg, Rebecca Gustafsson, Pavel Antonsson, Henrik Hedelin

“…Congenital insensitivity to pain with anhidrosis is caused by a mutation in the neurotrophic receptor tyrosine kinase 1 gene (NRTK1). The condition is characterized by multiple injuries, recurrent infections, and mental retardation. …”
Get full text

EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report by Hiroyuki Fujii, MD, Yusuke Okuma, MD, PhD, Makoto Hirata, MD, PhD, Yuki Shinno, MD, PhD, Tatsuya Yoshida, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Yuichiro Ohe, MD, PhD

“…Remarkably, despite the presence of EGFR mutation, the response to EGFR-tyrosine kinase inhibitor was poor, whereas the response to cytotoxic anticancer drugs and immunotherapy was favorable. …”
Get full text

Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application by Kaichun Li, Jin Li

“…Second-line treatment of advanced gastric cancer with ramucirumab, an antibody targeting VEGFR-2, alone or in combination with paclitaxel, has been proved to provide a beneficial effect. The VEGFR-2 tyrosine kinase inhibitor, apatinib, can improve the survival of advanced gastric cancer patients after second-line chemotherapy failure. …”
Get full text

Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years by Yoji Shido, Yukihiro Matsuyama

“…Pazopanib is a multitargeted tyrosine kinase inhibitor that has been clinically available from November 2012 in Japan. …”
Get full text

First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor by Rebecca Ganzon, Wei Chen, Gabriel Tinoco

“…Avapritinib is a tyrosine kinase inhibitor (TKI) approved in 2020 for adults with unresectable or metastatic gastrointestinal (GI) stromal tumors (GISTs) harboring a platelet-derived growth factor receptor alpha (PDGFRA) Exon 18 mutation, including D842V mutations. …”
Get full text

Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas by Ozden Oz, Asuman Argon, Tulu Ayata Kebat, Ozlem Ozdemir, Savas Yakan

“…Introduction and Aim: Pancreas Ductal Adenocarcinomas (PDACs) are among the leading causes of cancer-related death. Tyrosine kinase receptors (TKRs) are responsible for cell plasticity, chemoresistance, immunosuppression and metastasis potential. …”
Get full text

Role of Thyroid Hormone in Neurodegenerative Disorders of Older People by Arshag D. Mooradian, Michael J. Haas

“…The effect of THRP on cell viability is not modulated by c-Abl tyrosine kinase. The causal relationship between specific biochemical perturbations in cerebral tissue and thyroid dysfunction remains to be elucidated.…”
Get full text

A germline FLT3 variant in aplastic anemia by Lemchukwu C. Amaeshi, Amalia A. Sofianidi, Aditi Shastri, Mendel Goldfinger, Marina Konopleva, Amit K. Verma, Mark Chaitowitz, Ioannis Mantzaris

“…Abstract FMS-like tyrosine kinase 3 (FLT3) genetic variants are commonly seen in high-grade myeloid neoplasms and are typically gain-of-function mutations associated with a proliferative disease phenotype. …”
Get full text

ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility by Dalia de laFuente‐Vivas, Vincenzo Cappitelli, Rocío García‐Gómez, Sara Valero‐Díaz, Camilla Amato, Javier Rodriguéz, Santiago Duro‐Sánchez, Alexander vonKriegsheim, Michael Grusch, José Lozano, Joaquín Arribas, Berta Casar, Piero Crespo

“…Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. …”
Get full text

AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer by Pierre-Antoine Bannier, Charlie Saillard, Philipp Mann, Maxime Touzot, Charles Maussion, Christian Matek, Niklas Klümper, Johannes Breyer, Ralph Wirtz, Danijel Sikic, Bernd Schmitz-Dräger, Bernd Wullich, Arndt Hartmann, Sebastian Försch, Markus Eckstein

“…Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.g., erdafitinib) is approved for mUC and requires FGFR3 mutational testing. …”
Get full text

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment by Gregory W. Charville, Sukhmani K. Padda, Richard K. Sibley, Ajithkumar Puthillath, Paul Y. Kwo

“…We discuss the case of a 26-year-old female with a history of ROS1-rearranged lung adenocarcinoma, undergoing treatment with the tyrosine kinase inhibitor crizotinib, who presented to our hospital with abdominal pain and scleral icterus. …”
Get full text

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations by Abhimanyu Tushir, Israh Akhtar, Anjali Seth

“…The majority of these co-occurring alterations were detected in samples collected from patients with resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. …”
Get full text

Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature by Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick

“…These include the immunotherapeutics, alfa-interferon, and interleukin-2, and agents that target the vascular endothelial growth factor receptor (VEGFR) via its tyrosine kinase, such as sorafenib, sunitinib, and pazopanib, or the mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus. …”
Get full text

The Impact of Targeted Therapies on Red Blood Cell Aggregation in Patients with Chronic Lymphocytic Leukemia Evaluated Using Software Image Flow Analysis by Anika Alexandrova-Watanabe, Emilia Abadjieva, Lidia Gartcheva, Ariana Langari, Miroslava Ivanova, Margarita Guenova, Tihomir Tiankov, Velichka Strijkova, Sashka Krumova, Svetla Todinova

“…Despite advances in therapies targeting Bruton’s tyrosine kinase and anti-apoptotic protein BCL-2, little is known about their effect on red blood cell (RBC) aggregation in blood flow. …”
Get full text